INNEXUS UNVEILS DXL625 ANTI-CD20 MONOCLONAL ANTIBODY.InNexus Biotechnology Inc., British Columbia, a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL (Domino eXtensible Language) A version of XML for Domino-based data. An XSLT processor is used to convert DXL data to XML data for external use. See Lotus Notes. (TM)) technology, has announced that significant enhancement of critical performance factors for many monoclonal antibodies (MAbs) appears possible through a novel cross linking technology developed by the company. Laboratory studies of the company's first product candidate, DXL625 (CD20), for the prospective treatment of non-Hodgkin's lymphoma non-Hodg·kin's lymphoma n. Any of various malignant lymphomas characterized by the absence of Reed-Sternberg cells. Non-Hodgkin's lymphoma , indicated that DXL625, an anti-CD20 monoclonal antibody monoclonal antibody, an antibody that is mass produced in the laboratory from a single clone and that recognizes only one antigen. Monoclonal antibodies are typically made by fusing a normally short-lived, antibody-producing B cell (see immunity) to a fast-growing enhanced with InNexus' DXL(TM) technology, may afford greater potency, binding affinity, and related characteristics, than the parent compound. The data were presented as part of the Cancer Track at the IBC IBC International Building Code IBC Iraq Body Count IBC Institutional Biosafety Committee IBC Inflammatory Breast Cancer IBC International Business Company IBC Independence Blue Cross IBC Insurance Bureau of Canada IBC International Broadcasting Convention Life Science Drug Discovery and Development of Innovative Therapeutics (DDT DDT or 2,2-bis(p-chlorophenyl)-1,1,1,-trichloroethane, chlorinated hydrocarbon compound used as an insecticide. First introduced during the 1940s, it killed insects that spread disease and feed on crops. ) Conference in Boston, Mass. "Boosting proven monoclonal antibody products will yield critical medical and commercial advantages, making a growing multi-billion dollar product category even better," said Jeff Morhet, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of InNexus Biotechnology. "Our proof of principle demonstration suggests that DXL(TM) capabilities can be applied to a diverse range of late stage and prospective treatments. The data are an important example of how InNexus can improve biotherapeutic candidates, with possible advances in product life cycles, dosing, product stability, and other key parameters." The InNexus study utilized CD20 antibodies integrated with DXL(TM)- peptide. The modified antibodies were observed to have a higher binding affinity than the parent molecule. DXL(TM)-anti-CD20 antibodies were also seen as more potent inducers of apoptosis in cell-based assays. DXL(TM)-anti-HER2 antibodies were significantly more potent than the parent antibody in slowing tumor progression in a xenograft xenograft /xeno·graft/ (zen´o-graft) a graft of tissue transplanted between animals of different species; it may be concordant, disease model. InNexus recently announced the appointment of Thomas Kindt, M.D., former National Institute of Health (NIH "Not invented here." See digispeak. NIH - The United States National Institutes of Health. ) Director of Intramural intramural /in·tra·mu·ral/ (-mu´r'l) within the wall of an organ. in·tra·mu·ral adj. Occurring or situated within the walls of a cavity or organ. Research, to the position of Chief Scientific Officer. Also, last week the company announced that Jur Strobos, M.D., J.D. former Director of Policy Research in the Office of the Commissioner of the Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ), will serve as Chief Medical Officer for InNexus. Earlier this year, the company disclosed that Royalty Pharma had completed purchase of a royalty interest in up to two products targeting cancer based on InNexus' DXL(TM) antibody enhancement technology. Under the terms of the agreement, Royalty Pharma has paid for the first royalty interest for U.S. $2 million and holds an option to purchase a royalty interest in a second product for an additional U.S. $2 million. The total purchase price for the royalty interests may be increased by up to U.S. $30 million for the two products if certain conditions are fulfilled. About DXL(TM) Technology DXL(TM) technology works by integrating self-binding peptides into monoclonal antibodies, potentiating target binding. Modified antibodies "cluster" upon engaging the target receptor site, resulting in greater "molecular mass" at the point of association. This may facilitate cancer cell destruction in a target dependent manner by increasing apoptosis, antibody dependent cell cytotoxicity and complement-dependent cytotoxicity. In addition, DXL(TM) antibodies have significantly extended dissociation rates, as measured by surface plasmon resonance The excitation of surface plasmons by light is denoted as a surface plasmon resonance (SPR) for planar surfaces or localized surface plasmon resonance (LSPR) for nanometer-sized metallic structures. . About InNexus InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL(TM) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL(TM) antibodies utilize unique, novel and patented methods and technologies of InNexus. InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, visit http://www.ixsbio.com or call 480/862-7500. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion